[{"id":"2d611a75-574e-482e-91b3-3bf96d4e7ace","acronym":"CATCHAML","url":"https://clinicaltrials.gov/study/NCT04318678","created_at":"2021-01-18T20:55:40.221Z","updated_at":"2025-02-25T12:27:32.189Z","phase":"Phase 1","brief_title":"CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","source_id_and_acronym":"NCT04318678 - CATCHAML","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD123 • IL3RA","pipe":"","alterations":" ","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-24"},{"id":"7cd7c85e-4e1b-46fd-8491-96d1bcc8b391","acronym":"IMGN632-0802","url":"https://clinicaltrials.gov/study/NCT04086264","created_at":"2021-01-18T20:00:09.580Z","updated_at":"2025-02-25T12:27:19.012Z","phase":"Phase 1/2","brief_title":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","source_id_and_acronym":"NCT04086264 - IMGN632-0802","lead_sponsor":"AbbVie","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • pivekimab sunirine (PVEK)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 218","initiation":"Initiation: 11/06/2019","start_date":" 11/06/2019","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-24"},{"id":"a3758200-2675-4c3a-9e8c-8a19c87396ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04230265","created_at":"2023-08-14T10:11:02.629Z","updated_at":"2025-02-25T15:43:50.590Z","phase":"Phase 1","brief_title":"Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies","source_id_and_acronym":"NCT04230265","lead_sponsor":"AvenCell Europe GmbH","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AVC-101"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-11"},{"id":"36e68fbc-8506-4572-acf5-3e86f4ea808b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949125","created_at":"2023-08-14T10:11:12.134Z","updated_at":"2025-02-25T15:28:11.863Z","phase":"Phase 1","brief_title":"Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies","source_id_and_acronym":"NCT05949125","lead_sponsor":"AvenCell Europe GmbH","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AVC-201"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 01/03/2024","start_date":" 01/03/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-02-10"},{"id":"610f01eb-c68e-44f8-9b23-e46ae4e5528c","acronym":"GO-TAG","url":"https://clinicaltrials.gov/study/NCT05716009","created_at":"2023-02-08T18:00:15.099Z","updated_at":"2025-02-25T15:27:53.038Z","phase":"Phase 1","brief_title":"Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML","source_id_and_acronym":"NCT05716009 - GO-TAG","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD33 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["CD33 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 11/20/2023","start_date":" 11/20/2023","primary_txt":" Primary completion: 12/25/2027","primary_completion_date":" 12/25/2027","study_txt":" Completion: 12/25/2028","study_completion_date":" 12/25/2028","last_update_posted":"2025-02-10"},{"id":"1b4e994d-52e1-4f2a-9230-cf391cb47aea","acronym":"NCI-2023-03572","url":"https://clinicaltrials.gov/study/NCT06034470","created_at":"2023-09-13T14:09:48.343Z","updated_at":"2025-02-25T17:02:50.246Z","phase":"Phase 1","brief_title":"Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms","source_id_and_acronym":"NCT06034470 - NCI-2023-03572","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" Chr t(15;17)","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • fludarabine IV • pivekimab sunirine (PVEK) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-03"},{"id":"6f7d4152-8883-4202-b09b-1e6eca244083","acronym":"","url":"https://clinicaltrials.gov/study/NCT05233618","created_at":"2023-08-14T10:11:07.430Z","updated_at":"2025-02-25T17:01:40.560Z","phase":"Phase 1","brief_title":"Study of Tagraxofusp for Post-Transplant Maintenance for Patients with CD 123+ AML, MF and CMML (HSCT 002)","source_id_and_acronym":"NCT05233618","lead_sponsor":"Karen Ballen, MD","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elzonris (tagraxofusp-erzs) • SL-701"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-03"},{"id":"9604cfb1-e6e8-49f6-8502-880d232ccb42","acronym":"","url":"https://clinicaltrials.gov/study/NCT03113643","created_at":"2023-08-14T10:10:56.859Z","updated_at":"2024-07-02T16:34:27.434Z","phase":"Phase 1","brief_title":"SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","source_id_and_acronym":"NCT03113643","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 06/26/2017","start_date":" 06/26/2017","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-06-11"},{"id":"9436a8ff-5aa6-4f94-a70c-ecf2cecaa874","acronym":"NCI-2022-02215","url":"https://clinicaltrials.gov/study/NCT05285813","created_at":"2023-08-14T10:11:07.915Z","updated_at":"2024-07-02T16:34:58.922Z","phase":"Phase 2","brief_title":"A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure","source_id_and_acronym":"NCT05285813 - NCI-2022-02215","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vibecotamab (XmAb14045)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/06/2022","start_date":" 05/06/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-04"},{"id":"d849c811-e1a4-4e2a-879f-f191f73d4644","acronym":"TCD17197","url":"https://clinicaltrials.gov/study/NCT05086315","created_at":"2023-08-14T10:11:07.011Z","updated_at":"2024-07-02T16:35:00.248Z","phase":"Phase 1/2","brief_title":"First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","source_id_and_acronym":"NCT05086315 - TCD17197","lead_sponsor":"Sanofi","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bexatamig (IPH6101)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 12/11/2025","primary_completion_date":" 12/11/2025","study_txt":" Completion: 11/11/2026","study_completion_date":" 11/11/2026","last_update_posted":"2024-05-29"},{"id":"39c3282f-51bb-4fb8-ab95-8b0dcb862709","acronym":"","url":"https://clinicaltrials.gov/study/NCT05506956","created_at":"2023-08-14T10:11:09.789Z","updated_at":"2024-07-02T16:35:00.814Z","phase":"Phase 1","brief_title":"Post-transplant Flotetuzumab for AML","source_id_and_acronym":"NCT05506956","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 10/20/2022","start_date":" 10/20/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-27"},{"id":"619771d1-d4a0-44c2-8ac6-1aa798882b7f","acronym":"TAGALONG","url":"https://clinicaltrials.gov/study/NCT05442216","created_at":"2023-08-14T10:11:09.139Z","updated_at":"2024-07-02T16:35:06.443Z","phase":"Phase 2","brief_title":"Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents","source_id_and_acronym":"NCT05442216 - TAGALONG","lead_sponsor":"Joshua Zeidner","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-02"},{"id":"8a617f1a-04a1-44fa-9406-0c4b9b9170e3","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT03979508","created_at":"2021-01-18T19:34:12.469Z","updated_at":"2024-07-02T16:35:07.182Z","phase":"Phase 2","brief_title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","source_id_and_acronym":"NCT03979508 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1","pipe":" | ","alterations":" JAK2 amplification","tags":["HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-29"},{"id":"895fe5db-e691-4d01-907b-22d95cc3d747","acronym":"","url":"https://clinicaltrials.gov/study/NCT04051216","created_at":"2023-08-14T10:11:01.762Z","updated_at":"2025-02-25T14:28:33.736Z","phase":"","brief_title":"The SMART CART Study: Health Information Technology","source_id_and_acronym":"NCT04051216","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"],"overall_status":"Completed","enrollment":" Enrollment 148","initiation":"Initiation: 12/20/2017","start_date":" 12/20/2017","primary_txt":" Primary completion: 08/25/2023","primary_completion_date":" 08/25/2023","study_txt":" Completion: 11/23/2023","study_completion_date":" 11/23/2023","last_update_posted":"2024-03-22"},{"id":"bdb1c58a-74c6-4750-9dd9-d9830096d0d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03291444","created_at":"2021-01-18T16:15:39.130Z","updated_at":"2024-07-02T16:35:14.542Z","phase":"Phase 1","brief_title":"CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS","source_id_and_acronym":"NCT03291444","lead_sponsor":"Zhujiang Hospital","biomarkers":" KIT • CD20 • IL6 • CD38 • WT1 • CD22 • CD33 • CD34 • NCAM1 • MME • IL3RA","pipe":" | ","alterations":" CD20 positive","tags":["KIT • CD20 • IL6 • CD38 • WT1 • CD22 • CD33 • CD34 • NCAM1 • MME • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/05/2018","start_date":" 05/05/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-15"},{"id":"ac11fef2-00de-4d70-b80b-5c5887b96c6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05817058","created_at":"2023-08-14T10:11:11.877Z","updated_at":"2024-07-02T16:35:14.822Z","phase":"Phase 1","brief_title":"First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05817058","lead_sponsor":"Affimed GmbH","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFM28"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-13"},{"id":"93a602fc-fef4-4ca8-ada5-f9aa24df7e29","acronym":"","url":"https://clinicaltrials.gov/study/NCT05720988","created_at":"2023-08-14T10:11:11.619Z","updated_at":"2025-02-25T15:45:00.769Z","phase":"Phase 1","brief_title":"Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT05720988","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Elzonris (tagraxofusp-erzs)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/03/2024","start_date":" 08/03/2024","primary_txt":" Primary completion: 08/03/2025","primary_completion_date":" 08/03/2025","study_txt":" Completion: 08/03/2026","study_completion_date":" 08/03/2026","last_update_posted":"2024-03-08"},{"id":"883417c3-4016-4ca7-adfb-379f14c7fc53","acronym":"","url":"https://clinicaltrials.gov/study/NCT05476770","created_at":"2023-08-14T10:11:09.445Z","updated_at":"2024-07-02T16:35:18.062Z","phase":"Phase 1","brief_title":"Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies","source_id_and_acronym":"NCT05476770","lead_sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • vincristine • fludarabine IV • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 11/11/2025","primary_completion_date":" 11/11/2025","study_txt":" Completion: 11/11/2027","study_completion_date":" 11/11/2027","last_update_posted":"2024-02-22"},{"id":"0a2db8ff-cbd1-468b-a91f-239d3b97766f","acronym":"AMELI-01","url":"https://clinicaltrials.gov/study/NCT03190278","created_at":"2023-08-14T10:10:57.638Z","updated_at":"2024-07-02T16:35:20.952Z","phase":"Phase 1","brief_title":"Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03190278 - AMELI-01","lead_sponsor":"Cellectis S.A.","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UCART123"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 06/19/2017","start_date":" 06/19/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-05"},{"id":"9f422a88-402d-4776-a63e-899f8ce422df","acronym":"NCI-2014-01147","url":"https://clinicaltrials.gov/study/NCT02159495","created_at":"2021-01-18T10:03:02.202Z","updated_at":"2024-07-02T16:35:21.732Z","phase":"Phase 1","brief_title":"Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","source_id_and_acronym":"NCT02159495 - NCI-2014-01147","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["FLT3 • CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD123R(EQ)28zeta/EGFRt+ T cells • MB-102 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/15/2015","start_date":" 12/15/2015","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-01-30"},{"id":"f9804601-1b5e-4001-940c-6e9301ecc5f3","acronym":"CP-MGD024-01","url":"https://clinicaltrials.gov/study/NCT05362773","created_at":"2022-05-05T15:53:53.535Z","updated_at":"2024-07-02T16:35:23.328Z","phase":"Phase 1","brief_title":"A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies","source_id_and_acronym":"NCT05362773 - CP-MGD024-01","lead_sponsor":"MacroGenics","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGD024"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-01-17"},{"id":"a498e32c-b2f0-40fb-8597-93fddf2b2869","acronym":"","url":"https://clinicaltrials.gov/study/NCT06034275","created_at":"2023-09-13T14:09:45.731Z","updated_at":"2024-07-02T16:35:23.633Z","phase":"Phase 1","brief_title":"Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies","source_id_and_acronym":"NCT06034275","lead_sponsor":"Vincerx Pharma, Inc.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VIP943"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 09/13/2023","start_date":" 09/13/2023","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-12"},{"id":"2e1f45d7-114f-4454-9867-53cc8e8641d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04681105","created_at":"2021-01-19T20:46:40.489Z","updated_at":"2024-07-02T16:35:25.698Z","phase":"Phase 1","brief_title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","source_id_and_acronym":"NCT04681105","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["PD-L1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 11/18/2020","start_date":" 11/18/2020","primary_txt":" Primary completion: 05/05/2026","primary_completion_date":" 05/05/2026","study_txt":" Completion: 05/05/2026","study_completion_date":" 05/05/2026","last_update_posted":"2023-12-20"},{"id":"50591c7e-2bb2-4a10-8880-29d3224dc148","acronym":"PEPN1812","url":"https://clinicaltrials.gov/study/NCT04158739","created_at":"2023-12-11T17:16:23.292Z","updated_at":"2024-07-02T16:35:26.619Z","phase":"Phase 1","brief_title":"Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04158739 - PEPN1812","lead_sponsor":"Children's Oncology Group","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • flotetuzumab (MGD006) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-12-11"}]